title: Differential growth sensitivity to 4-cis-hydroxy-L-proline of transformed rodent cell lines.
abstract: The effect of 4-cis-hydroxy-L-proline (CHP), a proline analogue, on the anchorage-dependent and -independent growth of several transformed rodent cell lines was studied. Mouse NIH-3T3 fibroblasts transformed by a variety of different oncogenes (Ki-ras, mos, src, fms, fes, met, and trk) by a DNA tumor virus (SV40) or by a chemical carcinogen (N-methylnitrosourea) were all found to be more sensitive (50% inhibitory dose, 20 to 55 micrograms/ml) to the dose-dependent inhibitory effects of CHP on growth in monolayer culture than were NIH-3T3 cells (50% inhibitory dose, 120 micrograms/ml). CHP was generally found to be even more effective in inhibiting the growth of these transformed cells as colonies in soft agar than in monolayer cultures. In addition, rat embryo fibroblasts (CREF) and normal rat kidney fibroblasts (NRK) after transformation with a Ki-ras oncogene exhibit a similar increase in their sensitivity to CHP-induced growth inhibition. Treatment of NRK cells with transforming growth factor alpha (TGF-alpha) and beta (TGF-beta), which reversibly induces phenotypic transformation of these cells, increases their sensitivity to CHP to a level comparable with that observed in Ki-ras-transformed NRK cells (K-NRK). The growth inhibitory effects of CHP are reversible, since removal of CHP results in a normal resumption of cell growth. CHP uptake occurs primarily through the Na+- and energy-dependent neutral amino acid transport A system, which is 6- to 7-fold more elevated in K-NRK cells compared with NRK cells. Treatment of NRK cells with TGF-alpha and/or -beta increases the uptake of [3H]methylaminoisobutyric acid on the A system to a level that is similar to that found in K-NRK cells. The functions of the Na+/K+ and Na+/H+ exchange systems are apparently necessary for the enhanced A system activity, since ouabain and amiloride can inhibit the uptake of [3H]methylaminoisobutyric acid in K-NRK cells and in NRK cells treated with TGF-alpha and/or -beta. The activity of the A system is specifically increased in K-NRK and in TGF-alpha- and/or -beta-treated NRK cells, since the other two major neutral amino acid uptake systems, the ASC and the L systems, and the Ly+ system for basic amino acid uptake show no apparent changes in their activity in NRK cells after treatment with TGF-alpha and/or -beta or in these cells after transformation with the Ki-ras oncogene. These results suggest that the differential growth sensitivity to CHP of transformed rodent cells and of normal fibroblasts treated with TGF-alpha and/or -beta is due in part to an elevated uptake of this amino acid analogue on the neutral amino acid transport A system.
authors.affiliation: Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892.
authors.forename: F
authors.initials: F
authors.lastname: Ciardiello
authors.forename: B
authors.initials: B
authors.lastname: Sanfilippo
authors.forename: K
authors.initials: K
authors.lastname: Yanagihara
authors.forename: N
authors.initials: N
authors.lastname: Kim
authors.forename: G
authors.initials: G
authors.lastname: Tortora
authors.forename: R H
authors.initials: RH
authors.lastname: Bassin
authors.forename: W R
authors.initials: WR
authors.lastname: Kidwell
authors.forename: D S
authors.initials: DS
authors.lastname: Salomon
mesh_terms: D000584:Amiloride / Q000494:pharmacology; D000596:Amino Acids / Q000378:metabolism; D000621:Aminoisobutyric Acids / Q000378:metabolism; D000818:Animals; D002352:Carrier Proteins / Q000032:analysis; D002461:Cell Line, Transformed; D003470:Culture Media; D006131:Growth Inhibitors / Q000494:pharmacology*; D006909:Hydroxyproline / Q000494:pharmacology*; D051379:Mice; D010042:Ouabain / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D017923:Sodium-Hydrogen Exchangers; D015291:Transforming Growth Factors
chemical_list: D000596:Amino Acids; D000621:Aminoisobutyric Acids; D002352:Carrier Proteins; D003470:Culture Media; D006131:Growth Inhibitors; D010455:Peptides; D017923:Sodium-Hydrogen Exchangers; C017911:2-(methylamino)isobutyric acid; D010042:Ouabain; D015291:Transforming Growth Factors; D000584:Amiloride; D006909:Hydroxyproline